Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.72), $0.05 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $10.73 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.